Home › Stopping GLP-1 treatment
Stopping GLP-1 treatment: what the evidence shows
About this page. Written by the GLPInfo editorial team with AI assistance from the official sources listed at the end, and approved by the site owner before publication. It has not been reviewed by a named clinician. Published 27 Aug 2026 · last updated 27 Aug 2026 · next scheduled review 27 Nov 2026.
This page is information, not medical advice. It never tells you which medicine, dose or format is right for you: those decisions sit with you and a qualified prescriber. Spotted an error? Tell us and we'll fix it fast.
The least marketed fact about these medicines is what the trials show when people stop. This page states it plainly, without using it to sell continuation: what happens next is a decision for you and a prescriber, made with the real numbers on the table.
What the withdrawal trials found
In SURMOUNT-4 (tirzepatide, published in JAMA in 2024), participants who lost weight over a 36-week lead-in and were then switched to placebo regained a large proportion of it over the following year, while those who continued treatment lost further weight. The STEP 1 extension study (semaglutide) observed that participants regained around two-thirds of their lost weight in the year after treatment and support stopped. Cardiometabolic improvements receded alongside. These are averages with individual variation in both directions, but the direction itself is consistent across the class.
Why this is not a moral failing
Obesity research increasingly treats these medicines the way blood-pressure treatment is treated: managing a chronic condition rather than curing it. Weight regain after stopping reflects the biology the medicine was counteracting, not weak will. Whatever you decide, decide it on that footing.
How stopping actually works
There is no mandated taper in the leaflets, but stopping is still a prescriber conversation: they can advise on timing (for example around the two-month pre-pregnancy stop for semaglutide), what to expect, what support continues, and what would trigger restarting. Stopping because of side effects has its own path: dose reductions or switching medicines are often available before full stop, and switching covers that ground.
The cost arithmetic of stopping and restarting
Restarting later usually means re-entering the titration ladder at a low dose and, if you change provider, losing new-customer pricing you already used. Anyone budgeting a pause should look at the multi-month totals in the true cost guide rather than the monthly price alone, and at the price index for where the market sits today.
Related: switching GLP-1 medicines · results timeline · true cost guide
Frequently asked questions
Will I regain weight if I stop?
The trial evidence says most people regain a substantial share of lost weight in the year after stopping: around two-thirds in the STEP 1 extension, and a large proportion in SURMOUNT-4's withdrawal arm. Individual results vary, and continued diet, activity and support shift the odds, but planning should start from the trial numbers, not the hope of being the exception.
Do I need to taper off?
The leaflets do not mandate a taper, but stopping remains a prescriber conversation: timing, expectations, ongoing support and restart criteria are all better decided than defaulted. Never simply let a subscription lapse without telling the prescriber.
Is stopping and restarting cheaper than continuing?
Usually not as much as it looks: restarting means re-titrating from a low dose, and often losing new-customer pricing. The true cost guide shows the multi-month arithmetic honestly.